News Release

Confirmed Validation for Drug Product (Tetrodin) and its Drug Substance

Date: September 7, 2000

CDNX Trading Symbol: WXI
World Wide Web: http://www.wextech.ca
E-mail: wex@wextech.ca

International Wex Technologies Inc. (the "Company") is pleased to announce that the Company has now received 2 Certificates of Analysis from a Canadian qualified laboratory. These 2 certificates validate the Company's Drug Product and Drug Substance both as to the quality and confirmation of the Chinese standard as manufactured and provided by our manufacturing subsidiary in China. The direct benefits to the Company are to reinforce that we have a good solid foundation on the testing and their results obtained in China plus provide the needed confidence to independent parties that are currently reviewing and have reviewed our documentation.

The Drug Product, Tetrodin, is the actual manufactured item that is administered at its prescribed safe level for humans. This validation allows the Company to make available a supply of the finished Drug Product for the start of Clinical trials in Canada. These trials will occur when the HPB (Health Protection Branch, Canada) gives permission for the commencement of Phase 1 trials. Phase 1 trials can commence after the HPB receives the Company's IND (Investigational New Drug) application and has approved the application.

The Drug Substance, TTX, is obtained from the natural raw material and processed through the Company's unique processing method and equipment (currently being patented). This Certificate of Analysis provides the Company the needed validation to file a drug master file (DMF) with HPB. An in depth dossier is required for this filing. Once this documentation has been filed, the Company can offer to sell the Drug Substance in any purity to any laboratory, research group, University, etc.; as a tool for research on the sodium channel blocker. International Wex Technologies Inc. now has the ability to produce TTX at a higher purity level and in greater volume, far exceeding any other known facility in the world.

This report will now form part of the material that will be presented to the HBP when it meets for its pre-IND meeting in Ottawa on Thursday August 31, 2000.

Tetrodin(HT) has been developed by the company primarily as a treatment for the symptoms associated with withdrawal from all opiate addictions such as morphine, opium, heroin and methadone. It is a non-narcotic pharmaceutical that has proven to be safe and effective and functions well in both primary withdrawal treatment and abstinence maintenance (longer term use) of drug addiction. The company has also begun tests on the usage of Tetrodin(HT) as a potent analgesic.

For additional information on Tetrodin(HT), view the IWT website at http://www.wextech.ca or call Howard Milne , V. P. Shareholder Communications, at 604-683-8880 or 1-800-722-7549.

Per: Donna Shum, Corporate Secretary

The Canadian Venture Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this News Release.